Resmed Inc (RMD)
All research reports and stock updates for Resmed Inc.
Stock Updates
Research Reports
Time to wake up
The recent news flow of 'miracle' weight loss drugs has significantly impacted the potential outlook for RMD.
Supplying the goods
RMD’s innovation with the AirSense10 card to cloud product coupled with global supply chain improvements delivered strong device volume growth above market expectations.
Extended supply shortage
The return to the CPAP market of Philips Electronics following its recall events has become subordinate to the huge backlog across the industry.
Heavy breathing
We are looking past the minutiae of the 4Q22 result with eyes firmly planted on the prize of how much market share ResMed can grab while Phillips is sidelined.
Ducks in a row
Pricing, volume, competition, and backlog factors are all in ResMed’s favour now.
Please, Sir, I want some more
ResMed’s manufacturing capacity can now ramp to full speed after side-stepping the choke point of 4G chip supply.
Losing the price inhibition
The Philips Electronics product recall event looks set to take another twist as ResMed considers raising product prices.
Would you like chips with that?
The incremental revenue opportunity that fell into ResMed’s lap due to a competitor product recall has been badly spoiled.
Sweet dreams
Philips Respironics, Resmed’s main competitor in respiratory products, has announced a 10% price increase for its entire range of sleep and respiratory products. The increase will also apply to the category of devices that have been recalled. This confirms that PHG plans to act rationally in the market and will not destroy industry prices to regain market share.
One horse race
Resmed’s golden opportunity to have the global flow generator market virtually to itself for an extended period is facing some supply chain issues.
Race against the recall
Resmed's 1Q22 update revealed the incremental flow generator sales benefit will skew towards the latter part of the year, but the company is still likely to make big market share gains while competitor Philips Respironics (PHG) is sidelined. RMD is possibly being deliberately conservative.